NMRA · XBRL financial data
Neumora Therapeutics financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (NMRA's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 42 | 39* | 46 | 49 | 61 | 46* | 52 | 39 | 41 | 45* | 39 | 29 |
| General and administrative | 15 | 11* | 14 | 15 | 16 | 17* | 19 | 15 | 12 | 14* | 14 | 13 |
| Total operating expenses | 57 | 114* | 60 | 64 | 77 | 63* | 71 | 54 | 58 | 58* | 53 | 42 |
| Operating income (loss) | (57) | (114)* | (60) | (64) | (77) | (63)* | (71) | (54) | (58) | (58)* | (53) | (42) |
| Interest income | — | — | — | — | 4 | 4* | 3 | 2 | 2 | 1* | 1 | 1 |
| Interest expense | — | — | — | — | 0 | 0* | 0 | 0 | 1 | 2* | 1 | 1 |
| Other income (expense) | (0) | (0)* | (0) | (0) | (0) | 0* | (0) | (0) | 0 | (0)* | 0 | (0) |
| Income tax expense (benefit) | — | year only | — | 0 | 0 | 0* | 0 | 0 | 0 | 0* | 0 | 0 |
| Net income (loss) | (53) | (109)* | (54) | (59) | (73) | (59)* | (68) | (53) | (57) | (59)* | (53) | (43) |
| Earnings per share, basic USD per share | (1.14) | — | (0.34) | (0.37) | (0.45) | (0.37)* | (0.42) | (0.33) | (0.35) | (0.35)* | (0.30) | (0.23) |
| Earnings per share, diluted USD per share | (1.14) | — | (0.34) | (0.37) | (0.45) | (0.37)* | (0.42) | (0.33) | (0.35) | (0.35)* | (0.30) | (0.23) |
| Weighted average shares, basic millions of shares | 47 | — | 158 | 159 | 160 | 161* | 161 | 162 | 162 | 169* | 180 | 185 |
| Weighted average shares, diluted millions of shares | 47 | — | 158 | 159 | 160 | 161* | 161 | 162 | 162 | 169* | 180 | 185 |
Balance sheet
CSVFiscal quarters (NMRA's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 412 | 374 | 183 | 151 | 276 | 142 | 127 | 125 | 129 | 183 | 147 | 117 |
| Marketable securities | 97 | 80 | 240 | 221 | 66 | 165 | 122 | 93 | 42 | — | — | — |
| Marketable securities, non-current | 10 | 10 | 0 | — | — | — | — | — | — | — | — | — |
| Prepaid and other current assets | 16 | 24 | 20 | 27 | 6 | 5 | 4 | 5 | 6 | 8 | 6 | 8 |
| Total current assets | 526 | 478 | 443 | 398 | 349 | 314 | 255 | 223 | 177 | 191 | 153 | 125 |
| Property and equipment, net | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Right-of-use asset | 6 | 5 | 4 | 3 | 3 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Total assets | 545 | 496 | 450 | 404 | 353 | 317 | 257 | 224 | 178 | 191 | 154 | 125 |
| Accounts payable | 2 | 0 | 1 | 1 | 6 | 3 | 1 | 1 | 1 | 3 | 5 | 4 |
| Accrued liabilities | 23 | 21 | 19 | 18 | 23 | 25 | 26 | 20 | 25 | 29 | 25 | 23 |
| Current portion of long-term debt | — | — | — | — | — | — | — | 20 | 20 | 60 | 60 | 60 |
| Total current liabilities | 29 | 25 | 25 | 23 | 32 | 30 | 28 | 21 | 26 | 32 | 30 | 28 |
| Long-term debt | — | — | — | — | — | 0 | — | 19 | 20 | 55 | 53 | 53 |
| Lease liability, non-current | 3 | 2 | 1 | — | — | 0 | — | 0 | 0 | 0 | 0 | 0 |
| Total liabilities | 32 | 27 | 26 | 23 | 32 | 30 | 28 | 41 | 46 | 87 | 83 | 81 |
| Accumulated deficit | (595) | (703) | (757) | (816) | (888) | (947) | (1,015) | (1,068) | (1,125) | (1,184) | (1,238) | (1,281) |
| Total stockholders' equity | 513 | 469 | 425 | 381 | 321 | 287 | 228 | 183 | 132 | 104 | 71 | 45 |
| Total liabilities and equity | 545 | 496 | 450 | 404 | 353 | 317 | 257 | 224 | 178 | 191 | 154 | 125 |
| Common shares outstanding (cover page) millions of shares | 153 | 159 | 160 | 160 | 162 | 162 | 162 | 162 | 167 | 182 | 185 | 188 |
Cash flows
CSVFiscal quarters (NMRA's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (53) | (109)* | (54) | (59) | (73) | (59)* | (68) | (53) | (57) | (59)* | (53) | (43) |
| Stock-based compensation | 6* | 6* | 7 | 13* | 10* | 10* | 9 | 7* | 6* | 7* | 7 | 7* |
| Depreciation and amortization | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* | 0* | 0* | 0 | 0* |
| Net cash from operating activities | (48)* | (51)* | (43) | (56)* | (33)* | (50)* | (59) | (52)* | (47)* | (48)* | (46) | (40)* |
| Purchases of property and equipment | 0* | 0* | — | — | — | — | — | — | — | — | — | — |
| Net cash from investing activities | 24* | 14* | (150) | 21* | 157* | (99)* | 44 | 30* | 51* | 43* | 0 | 0* |
| Proceeds from issuing common stock | — | 0* | — | — | — | — | — | — | — | — | — | — |
| Net cash from financing activities | 232* | (0)* | 2 | 3* | 2* | 16* | 0 | 18* | (0)* | 59* | 11 | 9* |
| Net change in cash | 208* | (38)* | (191) | (32)* | 125* | (134)* | (15) | (4)* | 5* | 53* | (35) | (30)* |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Neumora Therapeutics | 117 | not reported | (40)* | 187.9M | 3.0 quarters | 10-QJun 30, 2026 |
| Lifevantage | 15 | 42* | 4.8* | 12.5M | — | 10-KJun 30, 2026 |
| Veru | 24 | not reported | (5.5)* | 17.1M | 4.4 quarters | 10-QJun 30, 2026 |
| Medicinova | 25 | 0.5 | (1.9)* | 49.2M | 13.2 quarters | 10-QJun 30, 2026 |
| Whitehawk Therapeutics | 85 | 0 | (15)* | 57.0M | 13.1 quarters | 10-QJun 30, 2026 |
| PDS Biotechnology | 5.6 | not reported | (2.8)* | 56.0M | 2.0 quarters | 10-QJun 30, 2026 |
| Sutro Biopharma | 54 | 9.8 | (38)* | 16.6M | 4.3 quarters | 10-QJun 30, 2026 |
| Corbus Pharmaceuticals Holdings | 23 | not reported | (30)* | 19.3M | 4.0 quarters | 10-QJun 30, 2026 |
| iBio | 56 | 0* | (6.2)* | 64.3M | 14.1 quarters | 10-KJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.